Distribution of Hepatitis C Risk Factors and HCV Treatment Outcomes among Central Canadian Aboriginal
- PMID: 27446875
- PMCID: PMC4904644
- DOI: 10.1155/2016/8987976
Distribution of Hepatitis C Risk Factors and HCV Treatment Outcomes among Central Canadian Aboriginal
Abstract
Background. Aboriginal Canadians face many lifestyle risk factors for hepatitis C exposure. Methods. An analysis of Ottawa Hospital Viral Hepatitis Clinic (Ottawa, Canada) patients between January 2000 and August 2013 was performed. HCV infection risk factors and HCV treatment outcomes were assessed. Socioeconomic status markers were based on area-level indicators linked to postal codes using administrative databases. Results. 55 (2.8%) Aboriginal and 1923 (97.2%) non-Aboriginal patients were evaluated. Aboriginals were younger (45.6 versus 49.6 years, p < 0.01). The distribution of gender (63.6% versus 68.3% male), HIV coinfection (9.1% versus 8.1%), advanced fibrosis stage (29.2% versus 28.0%), and SVR (56.3% versus 58.9%) was similar between groups. Aboriginals had a higher number of HCV risk factors, (mean 4.2 versus 3.1, p < 0.001) with an odds ratio of 2.5 (95% confidence interval: 1.4-4.4) for having 4+ risk factors. This was not explained after adjustment for income, social deprivation, and poor housing. Aboriginal status was not related to SVR. Aboriginals interrupted therapy more often due to loss to follow-up, poor adherence, and substance abuse (25.0% versus 4.6%). Conclusion. Aboriginal Canadians have higher levels of HCV risk factors, even when adjusting for socioeconomic markers. Despite facing greater barriers to care, SVR rates were comparable with non-Aboriginals.
Figures
References
-
- McCombs J., Matsuda T., Tonnu-Mihara I., et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a department of veterans affairs clinical registry. JAMA Internal Medicine. 2014;174(2):204–212. doi: 10.1001/jamainternmed.2013.12505. - DOI - PubMed
-
- Harris R. J., Thomas B., Griffiths J., et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. Journal of Hepatology. 2014;61(3):530–537. doi: 10.1016/j.jhep.2014.05.008. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical